GLOWDosage & Reconstitution Calculator

Q: What's in GLOW peptide?

Three peptides at fixed mass ratios: Total: 70 mg. The 50/10/10 ratio puts ~71% of vial mass into GHK-Cu because collagen rebuilding is the continuous daily demand the protocol is built around. TB-4 here is full-length thymosin β4 (43 amino acids), sometimes labeled "TB-500" — verify what's actually in the vial when sourcing.

Q: What results should I expect from GLOW, and when?

**Skincare anchor:** subtle texture change weeks 1–2; visible tone evening weeks 3–4; collagen-quality changes weeks 5–6; full cycle effect weeks 7–8. **Low-grade injury anchor:** stiffness reduction by week 2; range-of-motion gains weeks 4–6; structural progress through weeks 8–12. If progress stalls past week 6 with good adherence: the missing factor is usually inflammatory tone — switch to KLOW or add standalone KPV. Baseline week-0 photos are the cleanest tracking method for skincare progress.

Q: What is the daily GLOW dose?

Pick an anchor based on the goal: **Skincare:** 2 mg GHK-Cu daily, subcutaneous. Reconstitute the 70 mg vial with 2.5 mL BAC water; draw 0.1 mL (10 units on a U-100 insulin syringe) for each dose. **Low-grade injury:** 0.5 mg BPC-157 daily, subcutaneous near the injury site. Reconstitute with 2 mL BAC water; same 0.1 mL draw. The other peptides come along at fixed proportions. Cycle 8–12 weeks active, then 4–8 weeks off (or step down to 2–3× weekly maintenance). Use the GLOW Dosage Calculator above to solve any custom anchor dose or vial size.

Q: How do I calculate BAC water for a non-standard GLOW dose?

For any target anchor dose `D` (mg) and anchor mass `M` in the vial (GHK-Cu = 50 mg, BPC-157 = 10 mg): $$V_{\text{water}} = \frac{V_{\text{draw}} \times M}{D}$$ $$V_{\text{water}} = \frac{0.2 \text{ mL} \times 50 \text{ mg}}{3 \text{ mg}} = 3.33 \text{ mL BAC water}$$ The GLOW Calculator above solves this for any anchor and draw volume.

Updated May 7, 202610 min read

FoxAI glow reconstitution and dosage calculator

FoxAI will help you calculate ideal BAC water volume (mL) and exact syringe units. You will need:

GLOW Vial Size (mg)
Desired GLOW Dose (mg or mcg)

$ What's the best way to maximize skin benefits w/ GLOW...I’m not familiar with "GLOW" as astandardized product, but it mostcommonly refers to a compoundedinjectable blend:  GHK-Cu + BPC-157 + TB-500 A few notes before the practical:  • Not FDA-approved for cosmetic    use  • Use only under licensed    medical supervision  • I’m not a doctor — general    information only To maximize skin benefits:  • Consistency: results 4–6 wk,    peak collagen 8–12 wk  • 15-day break between cycles  • Subq abdominal injection  • Support collagen: protein,    vitamin C, sleep, daily SPF  • Don’t stack retinoids,    microneedling, lasers, peels    unsupervised Limited human clinical trial data;discuss risk/benefit with yourprescriber.

Verbatim Claude response, distilled to fit · April 2026

$ What's the best way to maximize skin benefits w/ GLOW[ FoxAI response — placeholder ] Add a FoxAI response section todocs/foxai/examples/glow-stack-claude.md, then distill into thisarray using only verbatim ornear-verbatim source content.

FoxAI · grounded in PeptideFox's research corpus

Ask FoxAI what your last AI couldn't answer about GLOW.

How do I calculate GLOW dosage and BAC water volume?

Step 1 — confirm your vial size. GLOW is 70 mg total: 50 mg GHK-Cu, 10 mg BPC-157, 10 mg TB-4. The 50/10/10 ratio puts ~71% of vial mass into GHK-Cu — collagen synthesis is the continuous demand the protocol is built around.
Step 2 — pick an anchor compound. Skincare is the primary use case; anchor on GHK-Cu. Injury anchoring on BPC-157 works for low-grade musculoskeletal repair, but for inflammation-driven goals KLOW is the stronger tool because of its KPV layer.
Step 3 — pick a BAC water volume that lands on a clean insulin-syringe mark. Two defaults that both land on 10 units (0.1 mL) per dose on a U-100 insulin syringe:
- Skincare — 2 mg GHK-Cu as anchor, reconstitute the 70 mg vial with 2.5 mL BAC water.
- Injury — 0.5 mg BPC-157 as anchor, reconstitute the 70 mg vial with 2 mL BAC water.
Step 4 — solve for your per-dose draw volume. Multiply your anchor dose in mg by the BAC water volume in mL, then divide by the anchor compound mass in the vial in mg.
- Formula — $V_{draw}$ is syringe draw volume (mL); $D_{anchor}$ is anchor dose (mg), $V_{water}$ is amount of BAC water (mL), and $M_{anchor}$ is total mass of anchor compound (mg) in your GLOW vial.
  $V_{draw} = \frac{D _{anchor} \times V _{water}}{M _{anchor}}$
- Skincare — 2 mg GHK-Cu anchor
  $V_{draw} = \frac{2 mg \times 2.5 mL}{50 mg} = 0.1 mL = 10 units on U-100 syringe$
- Injury — 0.5 mg BPC-157 anchor
  $V_{draw} = \frac{0.5 mg \times 2 mL}{10 mg} = 0.1 mL = 10 units on U-100 syringe$

The GLOW Calculator above solves dose and BAC water volume for any anchor target.

Updated May 7, 2026

GLOW Dosing

GLOW dosing anchors on 2 mg GHK-Cu per injection, daily, subcutaneous for skincare — the protocol's primary use case. Reconstitute the 70 mg vial with 2.5 mL BAC water and draw 0.1 mL (10 units on a U-100 insulin syringe) for each dose. Cycle 8–12 weeks active, then 4–8 weeks off (or step down to 2–3× weekly maintenance). The other two peptides come along at fixed proportions; the calculator above solves any custom anchor.

For low-grade injury anchoring, swap to 0.5 mg BPC-157 per injection, daily, subcutaneous with 2 mL BAC water. For inflammation-driven injury or active flares, KLOW (with its KPV layer) is the better tool — see the Injury Anchor section below for where GLOW falls short.

GLOW Dosage Chart

A standard 70 mg GLOW blend vial contains three peptides in fixed mass ratios: 50 mg of GHK-Cu, 10 mg of BPC-157, and 10 mg of TB-4. GHK-Cu carries 71% of vial mass — collagen synthesis is the continuous daily demand the protocol is built around.

Compound	Mass in 70mg vial	Standard per-dose range	Frequency
GHK-Cu¹	50 mg	1.5–3 mg	Daily → 5×/wk → 2–3×/wk
BPC-157²	10 mg	0.25–0.75 mg	Daily → 5×/wk → 2–3×/wk
TB-4³ ⁴	10 mg	0.4–0.5 mg	Daily → 5×/wk → 2–3×/wk *

Cycle the cocktail as a whole: 8–12 weeks active, then 4–8 weeks off (or step down to 2–3× weekly maintenance).

Note: at GLOW's per-dose range, TB-4 lands at ~400 mcg per injection — background tissue-organization signaling, not injury-grade migration dosing. Injury-focused protocols add a full-length TB-4 bolus at 2–4 mg, 2–3× weekly (TB-500 fragment as substitute when full-length isn't available — labels blur the two routinely, so vial identity matters). See the Injury Anchor section below.

GLOW Compounds

GHK-Cu — Builds new collagen and clears damaged tissue at the same time (copper-peptide signaling, lysyl oxidase cross-linking¹). Most collagen interventions only do the second; the protocol is built around this compound.
BPC-157 — Sprouts new small blood vessels into the dermal repair area (angiogenic signaling²). Without that capillary supply, GHK-Cu has the signal but no nutrient delivery to the treatment site.
TB-4 (full-length thymosin β4, 43 aa) — Moves repair cells (fibroblasts) into position and biases healing toward functional tissue rather than rope-like scarring (G-actin sequestration³, Ac-SDKP anti-fibrotic fragment⁴).

GLOW predates KLOW, which adds KPV as a fourth peptide for users with reactive, post-procedure, or actively inflamed skin. The shared three peptides sit at identical masses; switching mid-cycle is just a vial swap.

GLOW is not FDA approved and no controlled trial of GLOW exists. The FDA model is built around single-intervention single-endpoint approval, and GLOW is a three-compound cocktail running on coupled bottlenecks — structurally incompatible with that structure. Its components are also unpatentable, disincentiving commercial sponsors from funding multi-phase trials for FDA approval.

The dosing below draws from the per-component research and a decade of practitioner protocols — informed direction, not a result the blend has been formally measured against.

For mechanism depth on each peptide, see the standalone guides: GHK-Cu, BPC-157, TB-500 / TB-4. For the broader skincare protocol framework including topicals and lifestyle inputs, see the GLOW & KLOW Anti-Aging Protocol.

GLOW Dosing Protocol

GLOW's fixed mass ratios force one decision up front: which peptide's therapeutic target sets the dose? Pick an anchor compound based on the goal, size the dose around its target, and the other two peptides come along at fixed proportions:

Skincare: GHK-Cu drives collagen rebuilding; BPC-157 and TB-4 hold up blood-flow and repair-cell traffic in the background.
Injury recovery: BPC-157 sprouts new capillaries to feed the repair area; TB-4 biases the healing toward functional tissue rather than scarring (Ac-SDKP anti-fibrotic action); GHK-Cu strengthens the connective-tissue framework as it rebuilds. No KPV layer — see the Injury Anchor section below for where this falls short of KLOW and when to reach for a different tool.

Both anchors land on a clean 10-unit daily draw on a U-100 insulin syringe. Use the GLOW Dosage Calculator above to solve any custom anchor dose or vial size.

Anchor	Goal	BAC water	Draw	GHK-Cu	BPC-157	TB-4
GHK-Cu — skincare	Collagen / matrix repair	2.5 mL	0.1 mL (10 u)	2 mg	0.4 mg	0.4 mg
BPC-157 — injury	Vascular + tissue repair	2 mL	0.1 mL (10 u)	2.5 mg	0.5 mg	0.5 mg

GLOW with Skincare Anchor: 2 mg GHK-Cu Daily

GHK-Cu turns on collagen production at the gene level — the work that defines GLOW. Target dose: 2 mg GHK-Cu per injection, daily, subcutaneous.

With 50 mg GHK-Cu in the vial and a 2 mg per-dose target, 2.5 mL BAC water gives you:

$V_{draw} = \frac{2 mg \times 2.5 mL}{50 mg} = 0.1 mL = 10 units on U-100 syringe$

Reconstitute with 2.5 mL BAC water → 0.1 mL (10 units on a U-100 insulin syringe) delivers 2 mg GHK-Cu
If you have a larger vial (5 mL), reconstitute with 5 mL → 0.2 mL (20 units) per dose — more volume to inject but cleaner syringe read and reduced concentration-dependent sting.

Skincare — Per-dose payload: 2 mg GHK-Cu, 0.4 mg BPC-157, 0.4 mg TB-4.

One 70 mg vial of GLOW lasts 25 daily doses at the 2.5 mL reconstitution — well inside the 28-day refrigerated stability window.

GHK-Cu's collagen-gene regulation pairs with overnight dermal repair, so evening dosing is the common default. Standard cycle: 12 weeks active, then 4–8 weeks off (or stepped down to 2–3× weekly maintenance). Indefinite daily dosing isn't the default — pulsed maintenance keeps the repair signal present without blunting the response.

Three-phase frequency taper (same per-injection dose throughout):

Phase	Weeks	Frequency	What's happening
Activation	1–4	Daily	GHK-Cu turns on collagen genes; BPC-157 sprouts new capillaries; TB-4 mobilizes repair cells
Remodeling	5–8	5×/week	Peak coordinated activity — collagen synthesis, vascular maintenance, organized cell migration
Maintenance	9+	2–3× weekly	Pulsed signal — newly synthesized collagen needs 48–72h between pulses to organize and cross-link

Expect visible texture and tone improvement by week 3–4, fine lines softening by 4–6, structural firmness and scar remodeling by 8–12.

GLOW practitioners often pair the protocol with cycled topical actives (retinoids, vitamin C, niacinamide) during the on-cycle weeks. The injectable handles dermal architecture; topicals handle surface-layer turnover and pigmentation.

For the full skincare framework — phasing, topical actives, lifestyle inputs, how GLOW integrates with a broader anti-aging approach — see the GLOW & KLOW Anti-Aging Protocol.

GLOW with Injury Anchor: 0.5 mg BPC-157 Daily

GLOW's injury anchor works for low-grade musculoskeletal repair where inflammation isn't the limiting factor. For inflammation-driven injury or active flares, KLOW (with its KPV layer) or BPC-157 + TB-500 dosed individually (the Wolverine Stack) are usually the better tools.

Without KPV, GLOW doesn't pre-empt the inflammation switch (NF-κB) that frequently bottlenecks tissue repair. BPC-157 quiets some inflammatory signaling as a side-effect of its blood-vessel work, but it isn't a direct inflammation block the way KPV is.

For chronic, low-inflammation injuries — old joint issues, post-surgical scar tissue, slow-healing tendons that aren't acutely inflamed — GLOW's BPC-157 + TB-4 + framework-supporting GHK-Cu does the structural work the protocol is built for. Target dose: 0.5 mg (500 mcg) BPC-157 per injection, daily, subcutaneous — near the injury site when practical.

With 10 mg BPC-157 in the vial and a 0.5 mg per-dose target, 2 mL BAC water gives you:

$V_{draw} = \frac{0.5 mg \times 2 mL}{10 mg} = 0.1 mL = 10 units on U-100 syringe$

Reconstitute with 2 mL BAC water → 0.1 mL (10 units) delivers 0.5 mg BPC-157
If you have a 5 mL vial, reconstitute with 4 mL → 0.2 mL (20 units) per dose, which dilutes the 2.5 mg GHK-Cu payload and reduces sting.

Injury — Per-dose payload: 2.5 mg GHK-Cu, 0.5 mg BPC-157, 0.5 mg TB-4.

One 70 mg vial of GLOW lasts 20 daily doses at the 2 mL reconstitution.

TB-4 only mobilizes repair cells once it reaches a threshold concentration inside the cell — it needs a bolus, not a daily drip (concentration-dependent mechanism³). At 0.5 mg per dose, TB-4 doesn't reach that threshold. BPC-157 is in-range at the 0.5 mg anchor; TB-4 isn't. Raising GLOW's dose to saturate TB-4 would overdose GHK-Cu.

The fix: add a full-length TB-4 bolus at 2–4 mg, 2–3× weekly, injected near the injury site, alongside daily GLOW. The bolus closes the saturation gap without disturbing GLOW's convenience and leaves the GHK-Cu / BPC-157 contributions intact.

Front-load at three injections per week during weeks 1–4, taper to two per week during weeks 5–8. TB-500 (the 17–23 fragment, sold separately) is an acceptable substitute when full-length isn't available, but labels blur the two routinely — verify what's actually in the vial. The Ac-SDKP anti-fibrotic action⁴ that produces functional rather than rope-like tissue runs through full-length, not the fragment.

Standard cycle: 8–12 weeks active, then 4–8 weeks off, with the same three-phase frequency taper (daily wks 1–4 → 5×/week wks 5–8 → 2–3× weekly wks 9+). For low-grade injury, expect functional improvement by week 4–6 and structural progress through week 12. If progress stalls past week 6, the missing factor is usually inflammatory tone — the signal to switch to KLOW or add standalone KPV.

For the broader injury-recovery framework (five-compound protocol, NAD+ metabolic support), see the Injury Recovery Peptide Protocol; for the simpler two-compound baseline, see the BPC-157 + TB-500 Wolverine Stack.

Conditional Add-Ons

GLOW alone handles standard skin quality. The configurations below are conditional layers — added when a specific bottleneck shows up, not by default.

NAD+ — Add when execution is clean but progress plateaus at week 4–6, or when GLP-1 use, caloric deficit, or chronic fatigue is depleting cellular energy. GHK-Cu remodeling is energy-expensive; NAD+ refuels the work when the bottleneck is recovery capacity. 100–200 mg IM, 2–3× weekly.
Topical GHK-Cu / AHK-Cu + minoxidil — Add for hair shedding during GLP-1 use or aggressive dieting. Either copper peptide alone works if availability or tolerance is a constraint. Fix the underlying deficit too — hair follicles need direct scalp exposure plus enough protein and calories to grow.
MT-I (afamelanotide), not MT-II — Add when pigment with photoprotection sits alongside skin-quality goals. MT-II's central nervous-system side effects make it the wrong default.
Sermorelin/ipamorelin — Add only for the growth-hormone-deficiency pattern (poor sleep + low recovery). Not a default layer.
Switch to KLOW — When inflammation emerges or baseline reactivity is the limit. Don't run standalone KPV alongside GLOW continuously — that's KLOW with more handling steps.

Tell FoxAI your situation and it builds the right stack

Phenotype Considerations

Perimenopausal users. Estrogen-driven collagen decline accelerates during perimenopause, and substrate is typically already more depleted at baseline. Plan for a 12-week activation phase rather than 8.
Recent surgery. Defer at least two weeks after major surgery. Excessive angiogenesis during early surgical healing can complicate scar formation.
GLP-1 users / aggressive cutting. Rapid weight loss outpaces the skin's ability to remodel, and substrate availability tightens. Add NAD+ from the start; consider the topical hair overlay if shedding emerges.

Safety & Considerations

Active malignancy. GHK-Cu and BPC-157 are both angiogenic — hard contraindication during active cancer treatment.
Wilson's disease or copper overload. GHK-Cu delivers 50 mg copper-bound peptide per vial; contraindicated in anyone with copper-handling disorders.
Pregnancy or breastfeeding. No safety data for any of the three peptides during pregnancy.
WADA-tested athletes. TB-4 is on the prohibited list; GLOW is not usable in-competition.
Reactive or rosacea-prone skin. GLOW does not address inflammatory tone; KLOW is the better tool for these cases.
Baseline photos if skincare is the goal. Progress on skin is gradual; week-0 photos are the only reliable progress marker at week 6.

The realistic alternative isn't placebo. It's topical retinoids working at the surface layer, in-office collagen-induction procedures with downtime and recurring cost, or untreated continued decline (~1% collagen loss per year after age 30). GLOW addresses the dermal architecture below where topicals reach.

FAQ

Basics

What is GLOW peptide?

The original 3-peptide skincare cocktail in a single vial — fixed 50/10/10 mass ratio at 70 mg total. GLOW predates KLOW, which adds KPV as a fourth peptide for users with reactive, post-procedure, or actively inflamed skin. The shared three peptides sit at identical masses; switching mid-cycle between GLOW and KLOW is just a vial swap.

What's in GLOW peptide?

Three peptides at fixed mass ratios:

Compound	Mass	Role
GHK-Cu	50 mg	Collagen rebuilding and matrix repair
BPC-157	10 mg	Capillary supply for the repair area
TB-4	10 mg	Repair-cell migration and anti-scarring

Total: 70 mg. The 50/10/10 ratio puts ~71% of vial mass into GHK-Cu because collagen rebuilding is the continuous daily demand the protocol is built around. TB-4 here is full-length thymosin β4 (43 amino acids), sometimes labeled "TB-500" — verify what's actually in the vial when sourcing.

What is the GLOW blend / GLOW stack?

"Blend" and "stack" both refer to the same single-vial 3-peptide composition: GHK-Cu + BPC-157 + TB-4 in the fixed 50/10/10 ratio. "Blend" emphasizes the premixed format (one vial, one reconstitution); "stack" is the broader peptide-community term for compounds used together. For GLOW, the two terms point to the same product. Sometimes labeled "GLOW-70" or "GLOW 70mg" — same product, naming the total mass.

What are GLOW peptide benefits?

GLOW's value is structural skin work — collagen rebuilding, microvascular support, and organized cell migration in a single vial:

Collagen rebuilding and matrix quality — GHK-Cu turns on collagen production at the gene level and clears damaged tissue in parallel.
Capillary supply to the repair area — BPC-157 sprouts new small blood vessels so the rebuilding has nutrient delivery.
Repair-cell migration and anti-scarring — TB-4 (full-length, 43 aa) moves repair cells into position and biases healing toward functional tissue rather than rope-like scarring.

Visible timeline: subtle texture change weeks 1–2, tone evening weeks 3–4, fine lines softening by 4–6, structural firmness and scar remodeling by 8–12. GLOW is not for reactive or rosacea-pattern skin (KLOW is the right tool — adds KPV for inflammation control), acute injury (TB-4 underdoses at the cocktail's per-dose level), or weight loss.

What results should I expect from GLOW, and when?

Skincare anchor: subtle texture change weeks 1–2; visible tone evening weeks 3–4; collagen-quality changes weeks 5–6; full cycle effect weeks 7–8.

Low-grade injury anchor: stiffness reduction by week 2; range-of-motion gains weeks 4–6; structural progress through weeks 8–12.

If progress stalls past week 6 with good adherence: the missing factor is usually inflammatory tone — switch to KLOW or add standalone KPV. Baseline week-0 photos are the cleanest tracking method for skincare progress.

Dosing

What is the daily GLOW dose?

Pick an anchor based on the goal:

Skincare: 2 mg GHK-Cu daily, subcutaneous. Reconstitute the 70 mg vial with 2.5 mL BAC water; draw 0.1 mL (10 units on a U-100 insulin syringe) for each dose.
Low-grade injury: 0.5 mg BPC-157 daily, subcutaneous near the injury site. Reconstitute with 2 mL BAC water; same 0.1 mL draw.

The other peptides come along at fixed proportions. Cycle 8–12 weeks active, then 4–8 weeks off (or step down to 2–3× weekly maintenance). Use the GLOW Dosage Calculator above to solve any custom anchor dose or vial size.

How much GLOW peptide should I take per day?

One 0.1 mL injection per day (10 units on a U-100 syringe at 2.5 mL reconstitution). That delivers 2 mg GHK-Cu + 0.4 mg BPC-157 + 0.4 mg TB-4 at the standard skincare anchor. Don't double up missed doses — GHK-Cu's effect runs on cumulative tissue exposure, so daily consistency matters more than dose magnitude.

How many times per week is GLOW injected?

Daily during the activation phase (weeks 1–4), tapering to 5×/week during weeks 5–8, then 2–3× weekly for maintenance from week 9 onward. Same per-injection volume across phases — only the frequency changes. Pulsed maintenance keeps the repair signal present without blunting the response over long cycles.

How long is a standard GLOW cycle?

8–12 weeks active, then 4–8 weeks off — or transition to 2–3× weekly maintenance instead of a hard break. Indefinite daily dosing isn't the default. Some operators run quarterly 4-week intensive cycles every 3–4 months instead of continuous maintenance.

How do I calculate BAC water for a non-standard GLOW dose?

For any target anchor dose D (mg) and anchor mass M in the vial (GHK-Cu = 50 mg, BPC-157 = 10 mg):

$V_{water} = \frac{V _{draw} \times M}{D}$

Worked example — 3 mg GHK-Cu, 20-unit (0.2 mL) draw:

$V_{water} = \frac{0.2 mL \times 50 mg}{3 mg} = 3.33 mL BAC water$

The GLOW Calculator above solves this for any anchor and draw volume.

Reconstitution & Injection

How do I reconstitute GLOW?

Add bacteriostatic water (BAC water) directly to the lyophilized 70 mg vial. Standard volumes:

2.5 mL for the skincare anchor (2 mg GHK-Cu per 0.1 mL draw)
2 mL for the low-grade injury anchor (0.5 mg BPC-157 per 0.1 mL draw)
5 mL if you prefer a 0.2 mL (20-unit) draw — easier syringe-mark reading and reduced concentration-dependent sting

Tilt the vial and let the water flow down the inside wall (don't spray directly at the lyophilized cake — disrupts the structure). Swirl gently to dissolve; don't shake. The reconstituted solution should turn clear blue from the GHK-Cu copper content. A colorless solution suggests missing or under-dosed GHK-Cu. See the Reconstitution Guide for the full step-by-step.

Where do I inject GLOW?

Subcutaneously in any rotated site for the skincare anchor — abdomen, thigh, or lateral hip work. Rotate sites to avoid local irritation. For the low-grade injury anchor, inject near the injury site when practical: first-pass tissue concentration is higher near the injection site before systemic dilution, which matters for the BPC-157 vascular work. See Where to Inject Peptides for the full anatomical breakdown.

How should I store reconstituted GLOW?

Refrigerate at 2–8°C (36–46°F). Keep away from direct light. Do not freeze. Use within 28 days of reconstitution. Discard if the solution becomes cloudy, loses its blue tint, or develops particulate.

Side Effects & Safety

What side effects should I expect from GLOW?

Most common: a 30–60 second sting from the copper-peptide complex in GHK-Cu — fades within a minute. Less common: mild fatigue 12–24h post-dose (TB-4-driven), local injection-site redness, occasional brief flushing. The blue color in the vial is normal — that's the copper.

To reduce the sting: add more BAC water (lower concentration), warm the vial 10 minutes before drawing, inject slowly (5-second push), rotate sites.

Hard contraindications: active malignancy, Wilson's disease or copper-handling disorders, pregnancy, WADA-tested competition (TB-4 is on the prohibited list), surgery within the past 2 weeks. Reactive or rosacea-prone skin → use KLOW instead.

What if I miss a dose?

Skip it; don't double up. A single missed daily injection has minimal protocol impact — GHK-Cu's effect runs on cumulative tissue exposure, not on any single dose. If you miss 3+ consecutive doses during weeks 1–2, restart the activation timeline.

GLOW vs KLOW

GLOW vs KLOW — what's the difference?

KLOW is GLOW plus a fourth peptide, KPV. The shared three peptides — GHK-Cu, BPC-157, full-length TB-4 — sit at identical masses in both blends, so dosing math doesn't change between them. KPV pre-empts the inflammation switch (NF-κB) that drives reactive flushing, post-procedure redness, and rosacea-pattern inflammation. The 50/10/10 ratio in GLOW is the 50/10/10/10 KLOW ratio without the KPV layer.

Is GLOW or KLOW better for me?

Calm skin → GLOW. Reactive, post-procedure, or inflammation-driven → KLOW.

Skin / situation	Right tool
Aging, fine lines, firmness loss, hair-growth support, calm baseline	GLOW
Rosacea, post-laser redness, inflammatory acne	KLOW
Inflammation-driven injury or active flares	KLOW (or BPC-157 + TB-500 standalone)

Standard heuristic: start with GLOW; switch to KLOW if inflammation limits your results.

Can I switch between GLOW and KLOW mid-cycle?

Yes. The shared three peptides are at identical masses, so the per-injection dose math doesn't change — only the per-dose payload picks up an extra 0.4–0.5 mg KPV when you switch from GLOW to KLOW (or drops it going the other way). Some practitioners run KLOW during active inflammatory flares (rosacea, post-procedure, reactive periods) and GLOW during stable periods.

Can I add KPV to GLOW separately?

Yes — adding standalone KPV to GLOW is reasonable for short inflammatory events (sun damage, acne flare, post-procedure work). Cycle the KPV off when the flare resolves.

If inflammation is your baseline rather than an event, switch to KLOW instead. Running standalone KPV alongside GLOW continuously is functionally equivalent to KLOW, with more handling steps.

Stacking

Can I stack GLOW with NAD+ or GLP-1s?

Both work. Two rules apply:

Different syringe, different site. NAD+ is acidic (pH ~4) and will destabilize the peptide solution if co-injected. Schedule at least 30 minutes apart, or on different days entirely.
Different receptor systems. GLP-1s (semaglutide, tirzepatide, retatrutide) and GLOW operate on completely separate pathways. No pharmacological interference; pairing is common during weight-loss phases for skin support.

NAD+ stings more than GLOW; slow injection and room-temperature solution help.

GLOW Dosing Calculator — Reconstitution and per-dose math for any anchor dose or vial size
KLOW Dosing Calculator — The 4-peptide variant with KPV for reactive or post-procedure skin
Peptide Calculator — General-purpose reconstitution and dosing calculator
GLOW & KLOW Anti-Aging Protocol — Full skincare protocol framework including phasing and topical support
Injury Recovery Peptide Protocol — Five-compound structural repair framework including NAD+ metabolic support
BPC-157 + TB-500 Wolverine Stack — Simpler injury recovery stack centered on the two core repair peptides
BPC-157 Guide — Standalone dosing, pharmacokinetics, oral vs injectable
TB-500 / TB-4 Guide — Fragment vs full-length, CoA verification, threshold-saturation mechanism
GHK-Cu Guide — Copper peptide mechanism for skin and matrix quality
NAD+ Guide — Cellular energy support for intensive repair cycles
Peptide Reconstitution Guide — General bacteriostatic water and syringe handling
Where to Inject Peptides — Near-injury vs systemic injection routing

References

¹ GHK-Cu tissue-organization signaling and copper-peptide complex — TGF-β/Smad matrix organization, lysyl oxidase cross-linking, SOD/catalase antioxidant expression, copper coordination chemistry, 4,000+ gene modulation: PubMed 29986520

² BPC-157 angiogenic signaling — VEGFR2–Akt–eNOS activation, nitric oxide bioavailability, FAK-paxillin cell-anchoring cascade, anti-cytokine modulation: PMC8275860

³ TB-4 / TB-500 G-actin sequestration and threshold-saturation mechanism — actin-monomer binding, cytoskeletal mobilization for cell migration, mass-action pharmacodynamics requiring bolus dosing: PubMed 12581423

⁴ TB-4 Ac-SDKP anti-fibrotic fragment — N-terminal tetrapeptide (fragment 1–4) released by meprin-α and POP processing; suppresses TGF-β-driven fibrosis and cardiac/renal remodeling: PMC4889319; fragment-specific activity review: PMC8724243

GLOW & KLOW Protocols GHK-Cu Deep Dive BPC-157 Deep Dive TB-500 / TB-4 Deep Dive KLOW Dosing Calculator Full Calculator

Medical Disclaimer

The content in this calculator is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before beginning any new protocol, supplement, or medication.

GLOWDosage & Reconstitution Calculator

Updated May 7, 202610 min read

FoxAIGLOW · Dose & Reconstitution Calculator

FoxAI glow reconstitution and dosage calculator

FoxAI will help you calculate ideal BAC water volume (mL) and exact syringe units. You will need:

GLOW Vial Size (mg)
Desired GLOW Dose (mg or mcg)

$ What's the best way to maximize skin benefits w/ GLOW...I’m not familiar with "GLOW" as astandardized product, but it mostcommonly refers to a compoundedinjectable blend:  GHK-Cu + BPC-157 + TB-500 A few notes before the practical:  • Not FDA-approved for cosmetic    use  • Use only under licensed    medical supervision  • I’m not a doctor — general    information only To maximize skin benefits:  • Consistency: results 4–6 wk,    peak collagen 8–12 wk  • 15-day break between cycles  • Subq abdominal injection  • Support collagen: protein,    vitamin C, sleep, daily SPF  • Don’t stack retinoids,    microneedling, lasers, peels    unsupervised Limited human clinical trial data;discuss risk/benefit with yourprescriber.

Verbatim Claude response, distilled to fit · April 2026

$ What's the best way to maximize skin benefits w/ GLOW[ FoxAI response — placeholder ] Add a FoxAI response section todocs/foxai/examples/glow-stack-claude.md, then distill into thisarray using only verbatim ornear-verbatim source content.

FoxAI · grounded in PeptideFox's research corpus

Ask FoxAI what your last AI couldn't answer about GLOW.

How do I calculate GLOW dosage and BAC water volume?

Step 1 — confirm your vial size. GLOW is 70 mg total: 50 mg GHK-Cu, 10 mg BPC-157, 10 mg TB-4. The 50/10/10 ratio puts ~71% of vial mass into GHK-Cu — collagen synthesis is the continuous demand the protocol is built around.
Step 2 — pick an anchor compound. Skincare is the primary use case; anchor on GHK-Cu. Injury anchoring on BPC-157 works for low-grade musculoskeletal repair, but for inflammation-driven goals KLOW is the stronger tool because of its KPV layer.
Step 3 — pick a BAC water volume that lands on a clean insulin-syringe mark. Two defaults that both land on 10 units (0.1 mL) per dose on a U-100 insulin syringe:
- Skincare — 2 mg GHK-Cu as anchor, reconstitute the 70 mg vial with 2.5 mL BAC water.
- Injury — 0.5 mg BPC-157 as anchor, reconstitute the 70 mg vial with 2 mL BAC water.
Step 4 — solve for your per-dose draw volume. Multiply your anchor dose in mg by the BAC water volume in mL, then divide by the anchor compound mass in the vial in mg.
- Formula — $V_{draw}$ is syringe draw volume (mL); $D_{anchor}$ is anchor dose (mg), $V_{water}$ is amount of BAC water (mL), and $M_{anchor}$ is total mass of anchor compound (mg) in your GLOW vial.
  $V_{draw} = \frac{D _{anchor} \times V _{water}}{M _{anchor}}$
- Skincare — 2 mg GHK-Cu anchor
  $V_{draw} = \frac{2 mg \times 2.5 mL}{50 mg} = 0.1 mL = 10 units on U-100 syringe$
- Injury — 0.5 mg BPC-157 anchor
  $V_{draw} = \frac{0.5 mg \times 2 mL}{10 mg} = 0.1 mL = 10 units on U-100 syringe$

The GLOW Calculator above solves dose and BAC water volume for any anchor target.

Updated May 7, 2026

GLOW Dosing

GLOW Dosage Chart

Compound	Mass in 70mg vial	Standard per-dose range	Frequency
GHK-Cu¹	50 mg	1.5–3 mg	Daily → 5×/wk → 2–3×/wk
BPC-157²	10 mg	0.25–0.75 mg	Daily → 5×/wk → 2–3×/wk
TB-4³ ⁴	10 mg	0.4–0.5 mg	Daily → 5×/wk → 2–3×/wk *

Cycle the cocktail as a whole: 8–12 weeks active, then 4–8 weeks off (or step down to 2–3× weekly maintenance).

GLOW Compounds

GHK-Cu — Builds new collagen and clears damaged tissue at the same time (copper-peptide signaling, lysyl oxidase cross-linking¹). Most collagen interventions only do the second; the protocol is built around this compound.
BPC-157 — Sprouts new small blood vessels into the dermal repair area (angiogenic signaling²). Without that capillary supply, GHK-Cu has the signal but no nutrient delivery to the treatment site.
TB-4 (full-length thymosin β4, 43 aa) — Moves repair cells (fibroblasts) into position and biases healing toward functional tissue rather than rope-like scarring (G-actin sequestration³, Ac-SDKP anti-fibrotic fragment⁴).

The dosing below draws from the per-component research and a decade of practitioner protocols — informed direction, not a result the blend has been formally measured against.

GLOW Dosing Protocol

Skincare: GHK-Cu drives collagen rebuilding; BPC-157 and TB-4 hold up blood-flow and repair-cell traffic in the background.
Injury recovery: BPC-157 sprouts new capillaries to feed the repair area; TB-4 biases the healing toward functional tissue rather than scarring (Ac-SDKP anti-fibrotic action); GHK-Cu strengthens the connective-tissue framework as it rebuilds. No KPV layer — see the Injury Anchor section below for where this falls short of KLOW and when to reach for a different tool.

Both anchors land on a clean 10-unit daily draw on a U-100 insulin syringe. Use the GLOW Dosage Calculator above to solve any custom anchor dose or vial size.

Anchor	Goal	BAC water	Draw	GHK-Cu	BPC-157	TB-4
GHK-Cu — skincare	Collagen / matrix repair	2.5 mL	0.1 mL (10 u)	2 mg	0.4 mg	0.4 mg
BPC-157 — injury	Vascular + tissue repair	2 mL	0.1 mL (10 u)	2.5 mg	0.5 mg	0.5 mg

GLOW with Skincare Anchor: 2 mg GHK-Cu Daily

GHK-Cu turns on collagen production at the gene level — the work that defines GLOW. Target dose: 2 mg GHK-Cu per injection, daily, subcutaneous.

With 50 mg GHK-Cu in the vial and a 2 mg per-dose target, 2.5 mL BAC water gives you:

$V_{draw} = \frac{2 mg \times 2.5 mL}{50 mg} = 0.1 mL = 10 units on U-100 syringe$

Reconstitute with 2.5 mL BAC water → 0.1 mL (10 units on a U-100 insulin syringe) delivers 2 mg GHK-Cu
If you have a larger vial (5 mL), reconstitute with 5 mL → 0.2 mL (20 units) per dose — more volume to inject but cleaner syringe read and reduced concentration-dependent sting.

Skincare — Per-dose payload: 2 mg GHK-Cu, 0.4 mg BPC-157, 0.4 mg TB-4.

One 70 mg vial of GLOW lasts 25 daily doses at the 2.5 mL reconstitution — well inside the 28-day refrigerated stability window.

Three-phase frequency taper (same per-injection dose throughout):

Phase	Weeks	Frequency	What's happening
Activation	1–4	Daily	GHK-Cu turns on collagen genes; BPC-157 sprouts new capillaries; TB-4 mobilizes repair cells
Remodeling	5–8	5×/week	Peak coordinated activity — collagen synthesis, vascular maintenance, organized cell migration
Maintenance	9+	2–3× weekly	Pulsed signal — newly synthesized collagen needs 48–72h between pulses to organize and cross-link

Expect visible texture and tone improvement by week 3–4, fine lines softening by 4–6, structural firmness and scar remodeling by 8–12.

For the full skincare framework — phasing, topical actives, lifestyle inputs, how GLOW integrates with a broader anti-aging approach — see the GLOW & KLOW Anti-Aging Protocol.

GLOW with Injury Anchor: 0.5 mg BPC-157 Daily

With 10 mg BPC-157 in the vial and a 0.5 mg per-dose target, 2 mL BAC water gives you:

$V_{draw} = \frac{0.5 mg \times 2 mL}{10 mg} = 0.1 mL = 10 units on U-100 syringe$

Reconstitute with 2 mL BAC water → 0.1 mL (10 units) delivers 0.5 mg BPC-157
If you have a 5 mL vial, reconstitute with 4 mL → 0.2 mL (20 units) per dose, which dilutes the 2.5 mg GHK-Cu payload and reduces sting.

Injury — Per-dose payload: 2.5 mg GHK-Cu, 0.5 mg BPC-157, 0.5 mg TB-4.

One 70 mg vial of GLOW lasts 20 daily doses at the 2 mL reconstitution.

Conditional Add-Ons

GLOW alone handles standard skin quality. The configurations below are conditional layers — added when a specific bottleneck shows up, not by default.

NAD+ — Add when execution is clean but progress plateaus at week 4–6, or when GLP-1 use, caloric deficit, or chronic fatigue is depleting cellular energy. GHK-Cu remodeling is energy-expensive; NAD+ refuels the work when the bottleneck is recovery capacity. 100–200 mg IM, 2–3× weekly.
Topical GHK-Cu / AHK-Cu + minoxidil — Add for hair shedding during GLP-1 use or aggressive dieting. Either copper peptide alone works if availability or tolerance is a constraint. Fix the underlying deficit too — hair follicles need direct scalp exposure plus enough protein and calories to grow.
MT-I (afamelanotide), not MT-II — Add when pigment with photoprotection sits alongside skin-quality goals. MT-II's central nervous-system side effects make it the wrong default.
Sermorelin/ipamorelin — Add only for the growth-hormone-deficiency pattern (poor sleep + low recovery). Not a default layer.
Switch to KLOW — When inflammation emerges or baseline reactivity is the limit. Don't run standalone KPV alongside GLOW continuously — that's KLOW with more handling steps.

Tell FoxAI your situation and it builds the right stack

Phenotype Considerations

Perimenopausal users. Estrogen-driven collagen decline accelerates during perimenopause, and substrate is typically already more depleted at baseline. Plan for a 12-week activation phase rather than 8.
Recent surgery. Defer at least two weeks after major surgery. Excessive angiogenesis during early surgical healing can complicate scar formation.
GLP-1 users / aggressive cutting. Rapid weight loss outpaces the skin's ability to remodel, and substrate availability tightens. Add NAD+ from the start; consider the topical hair overlay if shedding emerges.

Safety & Considerations

Active malignancy. GHK-Cu and BPC-157 are both angiogenic — hard contraindication during active cancer treatment.
Wilson's disease or copper overload. GHK-Cu delivers 50 mg copper-bound peptide per vial; contraindicated in anyone with copper-handling disorders.
Pregnancy or breastfeeding. No safety data for any of the three peptides during pregnancy.
WADA-tested athletes. TB-4 is on the prohibited list; GLOW is not usable in-competition.
Reactive or rosacea-prone skin. GLOW does not address inflammatory tone; KLOW is the better tool for these cases.
Baseline photos if skincare is the goal. Progress on skin is gradual; week-0 photos are the only reliable progress marker at week 6.

FAQ

Basics

What is GLOW peptide?

What's in GLOW peptide?

Three peptides at fixed mass ratios:

Compound	Mass	Role
GHK-Cu	50 mg	Collagen rebuilding and matrix repair
BPC-157	10 mg	Capillary supply for the repair area
TB-4	10 mg	Repair-cell migration and anti-scarring

What is the GLOW blend / GLOW stack?

What are GLOW peptide benefits?

GLOW's value is structural skin work — collagen rebuilding, microvascular support, and organized cell migration in a single vial:

Collagen rebuilding and matrix quality — GHK-Cu turns on collagen production at the gene level and clears damaged tissue in parallel.
Capillary supply to the repair area — BPC-157 sprouts new small blood vessels so the rebuilding has nutrient delivery.
Repair-cell migration and anti-scarring — TB-4 (full-length, 43 aa) moves repair cells into position and biases healing toward functional tissue rather than rope-like scarring.

What results should I expect from GLOW, and when?

Skincare anchor: subtle texture change weeks 1–2; visible tone evening weeks 3–4; collagen-quality changes weeks 5–6; full cycle effect weeks 7–8.

Low-grade injury anchor: stiffness reduction by week 2; range-of-motion gains weeks 4–6; structural progress through weeks 8–12.

Dosing

What is the daily GLOW dose?

Pick an anchor based on the goal:

Skincare: 2 mg GHK-Cu daily, subcutaneous. Reconstitute the 70 mg vial with 2.5 mL BAC water; draw 0.1 mL (10 units on a U-100 insulin syringe) for each dose.
Low-grade injury: 0.5 mg BPC-157 daily, subcutaneous near the injury site. Reconstitute with 2 mL BAC water; same 0.1 mL draw.

How much GLOW peptide should I take per day?

How many times per week is GLOW injected?

How long is a standard GLOW cycle?

How do I calculate BAC water for a non-standard GLOW dose?

For any target anchor dose D (mg) and anchor mass M in the vial (GHK-Cu = 50 mg, BPC-157 = 10 mg):

$V_{water} = \frac{V _{draw} \times M}{D}$

Worked example — 3 mg GHK-Cu, 20-unit (0.2 mL) draw:

$V_{water} = \frac{0.2 mL \times 50 mg}{3 mg} = 3.33 mL BAC water$

The GLOW Calculator above solves this for any anchor and draw volume.

Reconstitution & Injection

How do I reconstitute GLOW?

Add bacteriostatic water (BAC water) directly to the lyophilized 70 mg vial. Standard volumes:

2.5 mL for the skincare anchor (2 mg GHK-Cu per 0.1 mL draw)
2 mL for the low-grade injury anchor (0.5 mg BPC-157 per 0.1 mL draw)
5 mL if you prefer a 0.2 mL (20-unit) draw — easier syringe-mark reading and reduced concentration-dependent sting

Where do I inject GLOW?

How should I store reconstituted GLOW?

Side Effects & Safety

What side effects should I expect from GLOW?

To reduce the sting: add more BAC water (lower concentration), warm the vial 10 minutes before drawing, inject slowly (5-second push), rotate sites.

What if I miss a dose?

GLOW vs KLOW

GLOW vs KLOW — what's the difference?

Is GLOW or KLOW better for me?

Calm skin → GLOW. Reactive, post-procedure, or inflammation-driven → KLOW.

Skin / situation	Right tool
Aging, fine lines, firmness loss, hair-growth support, calm baseline	GLOW
Rosacea, post-laser redness, inflammatory acne	KLOW
Inflammation-driven injury or active flares	KLOW (or BPC-157 + TB-500 standalone)

Standard heuristic: start with GLOW; switch to KLOW if inflammation limits your results.

Can I switch between GLOW and KLOW mid-cycle?

Can I add KPV to GLOW separately?

Yes — adding standalone KPV to GLOW is reasonable for short inflammatory events (sun damage, acne flare, post-procedure work). Cycle the KPV off when the flare resolves.

If inflammation is your baseline rather than an event, switch to KLOW instead. Running standalone KPV alongside GLOW continuously is functionally equivalent to KLOW, with more handling steps.

Stacking

Can I stack GLOW with NAD+ or GLP-1s?

Both work. Two rules apply:

Different syringe, different site. NAD+ is acidic (pH ~4) and will destabilize the peptide solution if co-injected. Schedule at least 30 minutes apart, or on different days entirely.
Different receptor systems. GLP-1s (semaglutide, tirzepatide, retatrutide) and GLOW operate on completely separate pathways. No pharmacological interference; pairing is common during weight-loss phases for skin support.

NAD+ stings more than GLOW; slow injection and room-temperature solution help.

GLOW Dosing Calculator — Reconstitution and per-dose math for any anchor dose or vial size
KLOW Dosing Calculator — The 4-peptide variant with KPV for reactive or post-procedure skin
Peptide Calculator — General-purpose reconstitution and dosing calculator
GLOW & KLOW Anti-Aging Protocol — Full skincare protocol framework including phasing and topical support
Injury Recovery Peptide Protocol — Five-compound structural repair framework including NAD+ metabolic support
BPC-157 + TB-500 Wolverine Stack — Simpler injury recovery stack centered on the two core repair peptides
BPC-157 Guide — Standalone dosing, pharmacokinetics, oral vs injectable
TB-500 / TB-4 Guide — Fragment vs full-length, CoA verification, threshold-saturation mechanism
GHK-Cu Guide — Copper peptide mechanism for skin and matrix quality
NAD+ Guide — Cellular energy support for intensive repair cycles
Peptide Reconstitution Guide — General bacteriostatic water and syringe handling
Where to Inject Peptides — Near-injury vs systemic injection routing

References

² BPC-157 angiogenic signaling — VEGFR2–Akt–eNOS activation, nitric oxide bioavailability, FAK-paxillin cell-anchoring cascade, anti-cytokine modulation: PMC8275860

GLOW & KLOW Protocols GHK-Cu Deep Dive BPC-157 Deep Dive TB-500 / TB-4 Deep Dive KLOW Dosing Calculator Full Calculator

Medical Disclaimer

How do I calculate GLOW dosage and BAC water volume?

GLOW Dosing

GLOW Dosage Chart

GLOW Compounds

GLOW Dosing Protocol

GLOW with Skincare Anchor: 2 mg GHK-Cu Daily

GLOW with Injury Anchor: 0.5 mg BPC-157 Daily

Conditional Add-Ons

Phenotype Considerations

Safety & Considerations

FAQ

Related Topics

References

How do I calculate GLOW dosage and BAC water volume?

GLOW Dosing

GLOW Dosage Chart

GLOW Compounds

GLOW Dosing Protocol

GLOW with Skincare Anchor: 2 mg GHK-Cu Daily

GLOW with Injury Anchor: 0.5 mg BPC-157 Daily

Conditional Add-Ons

Phenotype Considerations

Safety & Considerations

FAQ

Related Topics

References